Nicolas Peruzzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nicolas Peruzzo has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Gabriel Lenz
Internal Medicine, AdventHealth, Orlando, FL
4 shared publications Gustavo Gössling
Hospital Regina, Novo Hamburgo, Brazil
4 shared publications- Milena Tumelero
Department of Medicine, UNOESC University, Joaçaba, SC, Brazil
3 shared publications - Rafael Alvim Pereira
Department of Medicine, Hospital Santa Casa, São José dos Campos, SP, Brazil
3 shared publications - Gabriel Barcellos
Department of Medicine, Faculdade de Ciências Médicas, São José dos Campos, SP, Brazil
2 shared publications Iuri Martin Goemann
Medical School , Unisinos, São Leopoldo/RS 93022-750 , Brazil
2 shared publications
Latest Publications
- 2 June 2026
- Published by Elsevier in Surgical Oncology
- Vol. 67, 102463
Molecular subtypes and lymph-node metastasis in endometrial cancer: An updated systematic review and meta-analysis
- 2 June 2026
- Published by Elsevier in Surgical Oncology
- Vol. 67, 102463
Molecular subtypes and lymph-node metastasis in endometrial cancer: An updated systematic review and meta-analysis
- 14 May 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 49 (8) , 1100-1107
Complications of Temporary Transvenous Cardiac Pacing by Access Site: A Systematic Review and Meta‐Analysis
Introduction: The femoral and internal jugular veins are the most commonly used access routes for TTVPM placement. Femoral access is associated with higher rates of infection and bleeding due to groin proximity, whereas jugular access may increase the risk of vascular injury or pneumothorax when performed without imaging guidance. Despite numerous observational studies comparing these access sites, the evidence remains inconclusive due to heterogeneous methodologies, small sample sizes, and varying definitions of complications. To address these limitations, we conducted a meta‐analysis to compare the relative safety and effectiveness of jugular versus femoral access for TTVPM placement. Methods: A comprehensive search of PubMed, Embase, and Cochrane was performed from June 28, 2025, without language restrictions. Eligible studies included adult patients (≥18 years) undergoing TTVPM placement and directly comparing femoral and jugular venous access. Trials were considered if they reported at least one of the following outcomes: bleeding, infection, lead repositioning, cardiac perforation, or other major procedural complications. Results and Discussion: Six observational studies published between 2013 and 2024 met the inclusion criteria and encompassed 2,267 patients from diverse clinical settings. Bleeding complications were reported in five studies ( n = 1,457), showing no statistically significant difference between access sites (RR 0.54; 95% CI 0.18–1.60; p = 0.27). Four studies ( n = 528) reported catheter‐related infections, demonstrating a significantly lower risk with jugular access (RR 0.25; 95% CI 0.11–0.53; p = 0.0003). Lead repositioning (RR 0.73; p = 0.46) and cardiac perforation (RR 0.50; p = 0.33) showed no significant differences. Conclusion: Jugular venous access for TTVPM placement is associated with a significantly lower risk of catheter‐related infections compared with femoral access, while rates of bleeding, lead repositioning, and cardiac perforation do not significantly differ between approaches. Jugular access may be preferred for patients expected to require prolonged pacing or those at high infection risk, whereas femoral access remains reasonable for short‐term or emergent indications.
- 14 May 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 49 (8) , 1100-1107
Complications of Temporary Transvenous Cardiac Pacing by Access Site: A Systematic Review and Meta‐Analysis
Introduction: The femoral and internal jugular veins are the most commonly used access routes for TTVPM placement. Femoral access is associated with higher rates of infection and bleeding due to groin proximity, whereas jugular access may increase the risk of vascular injury or pneumothorax when performed without imaging guidance. Despite numerous observational studies comparing these access sites, the evidence remains inconclusive due to heterogeneous methodologies, small sample sizes, and varying definitions of complications. To address these limitations, we conducted a meta‐analysis to compare the relative safety and effectiveness of jugular versus femoral access for TTVPM placement. Methods: A comprehensive search of PubMed, Embase, and Cochrane was performed from June 28, 2025, without language restrictions. Eligible studies included adult patients (≥18 years) undergoing TTVPM placement and directly comparing femoral and jugular venous access. Trials were considered if they reported at least one of the following outcomes: bleeding, infection, lead repositioning, cardiac perforation, or other major procedural complications. Results and Discussion: Six observational studies published between 2013 and 2024 met the inclusion criteria and encompassed 2,267 patients from diverse clinical settings. Bleeding complications were reported in five studies ( n = 1,457), showing no statistically significant difference between access sites (RR 0.54; 95% CI 0.18–1.60; p = 0.27). Four studies ( n = 528) reported catheter‐related infections, demonstrating a significantly lower risk with jugular access (RR 0.25; 95% CI 0.11–0.53; p = 0.0003). Lead repositioning (RR 0.73; p = 0.46) and cardiac perforation (RR 0.50; p = 0.33) showed no significant differences. Conclusion: Jugular venous access for TTVPM placement is associated with a significantly lower risk of catheter‐related infections compared with femoral access, while rates of bleeding, lead repositioning, and cardiac perforation do not significantly differ between approaches. Jugular access may be preferred for patients expected to require prolonged pacing or those at high infection risk, whereas femoral access remains reasonable for short‐term or emergent indications.
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500302
Premature Deaths and Life-Years Lost From Lack of Amivantamab in Brazil's Unified Health System
PURPOSE: Lung cancer remains a leading cause of cancer mortality in Brazil, with non–small cell lung cancer (NSCLC) accounting for 85% of cases, with 1.6% carrying epidermal growth factor receptor (EGFR) exon 20 mutations. In the phase I CHRYSALIS trial (ClinicalTrials.gov identifier: NCT02609776 ), amivantamab demonstrated a median overall survival (OS) of 22.8 months versus 8.3 months with docetaxel, the standard second-line Brazil's Unified Health System (SUS) therapy. Although the Brazilian Health Regulatory Agency approved amivantamab, the National Commission for the Incorporation of Technologies’ cost-effectiveness reviews result in an average 10-year delay before SUS incorporation. We aimed to estimate premature deaths and life-years lost attributable to this access gap. METHODS: Using National Institute of Cancer (INCA) data, we estimated SUS-eligible patients, NSCLC prevalence, and EGFR exon 20 frequency. Stage distribution and 5-year recurrence rates identify candidates for amivantamab. A hazard ratio (HR) was derived from the inverse exponential method (ln(2)/OS ratio). Preventable deaths were calculated as: eligible patients × (1 – HR). Life-years gained per patient were estimated as OS difference. RESULTS: Of the 26,548 new patients with lung cancer, 18,973 are SUS-eligible, 16,127 have NSCLC, and 258 have EGFR exon 20 mutations. Metastatic disease accounts for 114, whereas recurrences occur in 60 (stage III), eight (II), and four (I), totaling 186 candidates annually. With an HR of 0.364, the annual preventable death in the base-case scenario is equal to 186 × (1 – 0.364) × 95% = 112 patients. Over 10 years, 1,120 premature deaths and 1,353 life-years could be avoided. CONCLUSION: Delayed SUS incorporation of amivantamab may result in over a 1,000 preventable deaths and life-years lost among Brazilian EGFR exon 20–mutated NSCLC. Urgent real-world studies and cost-effectiveness analyses are needed.
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500302
Premature Deaths and Life-Years Lost From Lack of Amivantamab in Brazil's Unified Health System
PURPOSE: Lung cancer remains a leading cause of cancer mortality in Brazil, with non–small cell lung cancer (NSCLC) accounting for 85% of cases, with 1.6% carrying epidermal growth factor receptor (EGFR) exon 20 mutations. In the phase I CHRYSALIS trial (ClinicalTrials.gov identifier: NCT02609776 ), amivantamab demonstrated a median overall survival (OS) of 22.8 months versus 8.3 months with docetaxel, the standard second-line Brazil's Unified Health System (SUS) therapy. Although the Brazilian Health Regulatory Agency approved amivantamab, the National Commission for the Incorporation of Technologies’ cost-effectiveness reviews result in an average 10-year delay before SUS incorporation. We aimed to estimate premature deaths and life-years lost attributable to this access gap. METHODS: Using National Institute of Cancer (INCA) data, we estimated SUS-eligible patients, NSCLC prevalence, and EGFR exon 20 frequency. Stage distribution and 5-year recurrence rates identify candidates for amivantamab. A hazard ratio (HR) was derived from the inverse exponential method (ln(2)/OS ratio). Preventable deaths were calculated as: eligible patients × (1 – HR). Life-years gained per patient were estimated as OS difference. RESULTS: Of the 26,548 new patients with lung cancer, 18,973 are SUS-eligible, 16,127 have NSCLC, and 258 have EGFR exon 20 mutations. Metastatic disease accounts for 114, whereas recurrences occur in 60 (stage III), eight (II), and four (I), totaling 186 candidates annually. With an HR of 0.364, the annual preventable death in the base-case scenario is equal to 186 × (1 – 0.364) × 95% = 112 patients. Over 10 years, 1,120 premature deaths and 1,353 life-years could be avoided. CONCLUSION: Delayed SUS incorporation of amivantamab may result in over a 1,000 preventable deaths and life-years lost among Brazilian EGFR exon 20–mutated NSCLC. Urgent real-world studies and cost-effectiveness analyses are needed.
- 21 May 2025
- Published by Elsevier in Clinical Lung Cancer
- Vol. 26 (6) , e361-e373
Chemotherapy Plus Anti-PD-1 or Anti-PD-L1 in Advanced PD-L1–Negative Squamous Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
- 21 May 2025
- Published by Elsevier in Clinical Lung Cancer
- Vol. 26 (6) , e361-e373
Chemotherapy Plus Anti-PD-1 or Anti-PD-L1 in Advanced PD-L1–Negative Squamous Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
- 7 September 2023
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 389 (10) , e20
Lonomia obliqua Envenomation
- 7 September 2023
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 389 (10) , e20
Lonomia obliqua Envenomation
- 7 March 2023
- Published by Elsevier in The American Journal of Medicine
- Vol. 136 (7) , e136-e137
A Treatment-Naive Cancer Patient in Critical Condition
- 7 March 2023
- Published by Elsevier in The American Journal of Medicine
- Vol. 136 (7) , e136-e137
A Treatment-Naive Cancer Patient in Critical Condition
- 31 January 2023
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 30 (2)
Rat-tailed maggot urinary myiasis
A healthy young woman presented after passing a living organism during micturition. She had recently bathed in Brazilian Pantanal wetlands. A diagnosis was made.
- 31 January 2023
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 30 (2)
Rat-tailed maggot urinary myiasis
A healthy young woman presented after passing a living organism during micturition. She had recently bathed in Brazilian Pantanal wetlands. A diagnosis was made.
- 17 January 2023
- Published by Elsevier in The American Journal of Medicine
- Vol. 136 (5) , e87-e89
Wheezing in an Asthmatic Woman: Worsening Asthma or Something Else?
- 17 January 2023
- Published by Elsevier in The American Journal of Medicine
- Vol. 136 (5) , e87-e89
Wheezing in an Asthmatic Woman: Worsening Asthma or Something Else?